Picture [LSUS] – The Business Web Portal 650x65px
Document › Details

Pieris Pharmaceuticals, Inc.. (8/9/17). "Press Release: Pieris Pharmaceuticals Reports Financial Results for the Second Quarter Ended June 30, 2017 and Provides Corporate Update". Boston, MA.

Organisations Organisation Pieris Pharmaceuticals Inc. (Nasdaq: PIRS)
  Group Pieris (Group)
  Organisation 2 AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
Products Product Anticalin® scaffold technology
  Product 2 PRS-060/AZD1402 (anti-IL4Ra Anticalin, Pieris/AstraZeneca)
Index term Index term AstraZeneca–Pieris: anticalin technology, 201705– collab developm + commerc $57.5m upfront + near-term inhaled respiratory drugs incl PRS-060
Persons Person Yoder, Stephen S. (Steve) (Pieris 201001– CEO before MorphoSys Head Licensing + IP)
  Person 2 Brkulj, Mario (MacDougall 201511 VP before MorphoSys + Biocom)

Record changed: 2017-08-18


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Pieris (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top